🔗 Share this article

While the US proceeds with historic changes to its vaccine guidelines, an unexpected name appears in a surprising turn: Høeg, a Danish American physician and public health researcher who rose to prominence by questioning coronavirus vaccines in the pandemic and has zeroed in on potential fatalities after Covid immunization in her brief tenure at the Food and Drug Administration.

Scheduled Changes to Pediatric Vaccine Program

Agency leaders were set to unveil sweeping changes to the pediatric immunization program in December, synchronizing the US with Denmark’s vaccine program, it is understood – a major change that would put the US at odds with a large portion of the international standard with little proof for improved outcomes. The announcement has been pushed back until the next year.

In place of the director of the vaccine center, Høeg is set to address the audience at the meeting. She was newly appointed acting director of the FDA’s drug evaluation center, the fifth individual to lead the center this calendar year.

Consolidating Power at the Agency

Høeg's temporary position might represent a tighter collaboration between the drug and biologics divisions as Dr. Høeg and Dr. Prasad solidify control at the agency – and it signals a increased emphasis upon dismantling previously authorized immunizations at the FDA.

Høeg has repeatedly called for discontinuing some childhood vaccine recommendations in the US to become more similar to the Danish model, a nation with nationalized medicine and a number of inhabitants about the population of the state of Wisconsin.

To date statements, she has kept her attention on vaccines – usually the responsibility of Dr. Prasad, director of the FDA’s CBER – rather than medication approval.

Concerns Over Background

The appointee has no obvious background in pharmaceutical research, oversight or management, which has been customary for past heads of the Center for Biologics Evaluation and Research. She has worked at the FDA as a key advisor to the agency head and CBER since spring.

“It seems she lacks to have the requisite experience” for overseeing the pharmaceutical oversight division, remarked Dr. Jonathan Howard. “She has not conducted a randomized controlled trial. She lacks experience in leading a sizeable institution. She lacks background in drug approvals.”

Former commissioners of the center would “understand legal statutes and the underlying principles of medication creation”, noted Dr. Janet Woodcock. “Objectively, she has not acquired the kind of background that prior appointees who headed the center have had.”

The drug center has an enormous workload at the agency, Woodcock emphasized.

“Everybody just zeroes in on the innovative therapies, but the generic drug division authorizes numerous generic medications. There is also a biologic copycat branch, OTC medication office and other areas, and every single one have to be supervised,” Dr. Woodcock said. “The area you neglect, that is the part that I always told people is going to bite you.”

Additionally, a major leadership element to the job, which manages over 5,000 employees. “It is a massive management job, if you do it right,” she concluded.

Response and Controversial Initiatives

In response to inquiries about Dr. Høeg's qualifications and whether this appointment indicates more teamwork among agency officials on vaccines, a press secretary stated that the “questions rely on flawed premises”.

“This background is consistent with the responsibilities of her position,” the spokesperson stated, noting the months Dr. Høeg spent counseling the agency head on “drug safety and oversight research, including computational safety modeling and immunization monitoring”.

As the temporary head, Høeg assumes responsibility for the commissioner’s controversial expedited review system, a controversial one-day therapy clearance system that apparently concerned her former heads. “By what process are these drugs being chosen for this expedited pathway? Who makes the decisions?” Howard said. “There is a lot of lack of transparency happening at the agency right now.”

Overall, he remarked, “the FDA looks to be trending towards less stringent oversight of pharmaceuticals, except for immunizations.”

Documented Past Work on Immunizations

Concerning vaccines, Høeg has a more established, if problematic, history, some experts observe. She authored a study using non-validated crowd-sourced reports to determine the incidence of heart inflammation following COVID-19 vaccination. She counseled the state of Florida top health official Joseph Ladapo, who was said to have changed statistics to imply Covid vaccines are riskier than they are.

Among her “policy goals” for the current federal leadership encompassed altering rules for novel immunizations and halting “unnecessary” vaccines, she remarked following the vote on a online show. At the agency, Høeg has allegedly suggested barring adolescent males from getting Covid vaccinations.

“She’s an complete ideologue who begins with her beliefs and tailors the evidence to fit the data in a very deceptive, dishonest fashion,” Howard stated.

Consolidating Power and a “Campaign of Retribution”

Høeg became part of other contrarians, {like|